Allspring Global Investments Holdings LLC decreased its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,208,626 shares of the company's stock after selling 135,731 shares during the period. Allspring Global Investments Holdings LLC owned about 1.41% of HealthEquity worth $80,132,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in HQY. McGlone Suttner Wealth Management Inc. bought a new stake in shares of HealthEquity during the fourth quarter worth about $29,000. Castleview Partners LLC bought a new stake in HealthEquity during the 2nd quarter worth approximately $39,000. Lazard Asset Management LLC increased its position in HealthEquity by 117.9% in the 3rd quarter. Lazard Asset Management LLC now owns 549 shares of the company's stock valued at $40,000 after acquiring an additional 297 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of HealthEquity during the third quarter valued at $41,000. Finally, Fifth Third Bancorp lifted its holdings in shares of HealthEquity by 36.5% during the third quarter. Fifth Third Bancorp now owns 602 shares of the company's stock worth $44,000 after purchasing an additional 161 shares during the period. Institutional investors and hedge funds own 99.55% of the company's stock.
HealthEquity Stock Up 3.4 %
Shares of HQY stock traded up $2.69 on Wednesday, reaching $81.30. 759,854 shares of the company were exchanged, compared to its average volume of 612,192. HealthEquity, Inc. has a one year low of $48.86 and a one year high of $84.49. The company has a market cap of $6.98 billion, a price-to-earnings ratio of 127.03, a PEG ratio of 1.30 and a beta of 0.53. The company has a 50-day moving average of $80.69 and a 200-day moving average of $73.96. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76.
Analyst Ratings Changes
A number of research firms recently weighed in on HQY. Raymond James increased their price objective on HealthEquity from $90.00 to $95.00 and gave the company an "outperform" rating in a report on Wednesday, December 13th. KeyCorp raised their price objective on HealthEquity from $85.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, March 22nd. Royal Bank of Canada upped their target price on HealthEquity from $90.00 to $92.00 and gave the company an "outperform" rating in a report on Wednesday, March 20th. BTIG Research increased their price objective on shares of HealthEquity from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, March 20th. Finally, JMP Securities initiated coverage on shares of HealthEquity in a research note on Thursday, April 4th. They set a "mkt outperform" rating and a $101.00 target price for the company. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, HealthEquity currently has an average rating of "Moderate Buy" and an average price target of $96.17.
Check Out Our Latest Report on HQY
Insiders Place Their Bets
In related news, EVP Delano Ladd sold 2,499 shares of HealthEquity stock in a transaction on Friday, February 9th. The shares were sold at an average price of $80.00, for a total value of $199,920.00. Following the completion of the sale, the executive vice president now owns 49,996 shares of the company's stock, valued at approximately $3,999,680. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other HealthEquity news, EVP Delano Ladd sold 2,499 shares of HealthEquity stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $80.00, for a total transaction of $199,920.00. Following the completion of the transaction, the executive vice president now owns 49,996 shares in the company, valued at approximately $3,999,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the business's stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the sale, the chief executive officer now directly owns 126,635 shares of the company's stock, valued at $10,106,739.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,322 shares of company stock worth $5,682,895. Corporate insiders own 2.70% of the company's stock.
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
